Sulfateq

Description

Sulfateq develops SUL compounds from research into natural mitochondrial stress responses, using a distinct mechanism of action to address non-communicable diseases and other therapeutic indications involving impaired mitochondrial function.

Sulfateq is located in the Netherlands ecosystem.

Related

• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• ADmit THERAPEUTICSADmit THERAPEUTICS develops and commercializes MAP-AD®, an in vitro diagnostic test using mitochondrial DNA epigenetic biomarkers, NGS and…
• Enterprise TherapeuticsEnterprise Therapeutics researches and develops respiratory disease therapies, including inhaled ENaC blocker ETD001, to address mucus…
• BioatlantisBioatlantis supplies natural compounds from renewable marine and terrestrial resources, including seaweed extracts, that reduce stress by…
• Novo NordiskNovo Nordisk develops treatments and support for serious chronic diseases by applying scientific expertise and understanding of people’s…
• BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
• AAplagonAplagon develops a therapeutic called APAC, a vascular-injury targeting molecule that combines antiplatelet, anticoagulant, and…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• Osteo-PharmaOsteo-Pharma develops OsteoActivator technology that encapsulates low molecular weight bone-healing compounds in a biodegradable carrier to…